Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.
复制标题
DOI：
10.1371/journal.pmed.0020112
复制
发表时间：
2005-04
期刊：
影响因子：
15.8
通讯作者：
Shafer RW
中科院分区：
文献类型：
--
作者：
Kantor R;Katzenstein DA;Efron B;Carvalho AP;Wynhoven B;Cane P;Clarke J;Sirivichayakul S;Soares MA;Snoeck J;Pillay C;Rudich H;Rodrigues R;Holguin A;Ariyoshi K;Bouzas MB;Cahn P;Sugiura W;Soriano V;Brigido LF;Grossman Z;Morris L;Vandamme AM;Tanuri A;Phanuphak P;Weber JN;Pillay D;Harrigan PR;Camacho R;Schapiro JM;Shafer RW
随着抗逆转录病毒治疗扩大到世界上各种非B亚型病毒占主导地位的地区，HIV-1亚型之间的遗传差异可能对临床管理和耐药性监测至关重要。为了评估HIV-1亚型和抗逆转录病毒治疗对蛋白酶和逆转录酶突变分布的影响，使用亚型和治疗作为解释变量的二项式应答模型分析了非B亚型HIV-1序列的大型汇编数据集。我们分析了来自3,686名具有良好抗逆转录病毒治疗史的患者的非B亚型序列，并与来自4,769名患者的B亚型序列进行了比较。非B亚型序列包括461个A亚型、1,185个C亚型、331个D亚型、245个F亚型、293个G亚型、513个CRF01_AE亚型和618个CRF02_AG亚型。55个已知的B亚型耐药突变中的每一个都发生在至少一个非B分离株中，其中44个（80%）突变与至少一个非B亚型的抗逆转录病毒治疗显著相关。相反，在至少一种非B亚型中发现的与抗逆转录病毒治疗相关的67个突变中，61个也与B亚型分离株中的抗逆转录病毒治疗相关。全球耐药监测和基因型评估应主要关注已知的B亚型耐药突变。大多数研究都集中在HIV-1亚型B，尽管全世界大多数感染都是非B型。然而，这篇论文表明，相同的耐药突变发生在亚型之间
The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate. To assess the impact of HIV-1 subtype and antiretroviral treatment on the distribution of mutations in protease and reverse transcriptase, a binomial response model using subtype and treatment as explanatory variables was used to analyze a large compiled dataset of non-subtype-B HIV-1 sequences. Non-subtype-B sequences from 3,686 persons with well characterized antiretroviral treatment histories were analyzed in comparison to subtype B sequences from 4,769 persons. The non-subtype-B sequences included 461 with subtype A, 1,185 with C, 331 with D, 245 with F, 293 with G, 513 with CRF01_AE, and 618 with CRF02_AG. Each of the 55 known subtype B drug-resistance mutations occurred in at least one non-B isolate, and 44 (80%) of these mutations were significantly associated with antiretroviral treatment in at least one non-B subtype. Conversely, of 67 mutations found to be associated with antiretroviral therapy in at least one non-B subtype, 61 were also associated with antiretroviral therapy in subtype B isolates. Global surveillance and genotypic assessment of drug resistance should focus primarily on the known subtype B drug-resistance mutations. Most research has focused on HIV-1 subtype B, although most infections worldwide are non-B. However, this paper suggests that the same drug resistance mutations occur across subtypes
登录
查看更多内容
影响因子：
3.8
作者：
Landman, R;Schiemann, R;Ndoye, I
通讯作者：
Ndoye, I
DOI：
10.1097/00126334-200307010-00007
发表时间：
2003-07-01
影响因子：
3.6
作者：
Ariyoshi, K;Matsuda, M;Sugiura, W
通讯作者：
Sugiura, W
影响因子：
5.4
作者：
Apetrei, C;Descamps, D;Brun-Vézinet, F
通讯作者：
Brun-Vézinet, F
影响因子：
1.6
作者：
Caride, E;Hertogs, K;Tanuri, A
通讯作者：
Tanuri, A
DOI：
10.1111/j.2517-6161.1995.tb02031.x
发表时间：
1995-01-01
影响因子：
5.8
作者：
BENJAMINI, Y;HOCHBERG, Y
通讯作者：
HOCHBERG, Y